AFT Pharmaceuticals Limited expanded its co-operation with Hikma Pharmaceuticals to extend its license for Maxigesic/Combogesic IV, the intravenous form of the pain relief medicine, to Saudi Arabia, Iraq, and Jordan. Hikma is the licensee of the medicine in the US where it was recently launched.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,981 GBX | +0.41% | +2.91% | +10.73% |
05-03 | Deutsche Bank Starts Hikma Pharmaceuticals Coverage at Buy | MT |
05-03 | Jefferies cuts AJ Bell; Deutsche likes ConvaTec | AN |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+10.73% | 5.47B | |
+32.87% | 698B | |
+26.51% | 568B | |
-4.55% | 358B | |
+19.17% | 328B | |
+3.63% | 283B | |
+16.34% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+8.49% | 165B |
- Stock Market
- Equities
- HIK Stock
- News Hikma Pharmaceuticals PLC
- AFT Pharmaceuticals Limited Extends License for Maxigesic/Combogesic IV with Hikma Pharmaceuticals